Reducing drug costs using behavioural science

Strategies inspired by opt-in, opt-out approach of pensions

The health plan cost increases besieging Canadian companies are driven by many factors, including the availability of specialty drugs for treating rare and complex diseases. But the primary driver of drug cost inflation is a lack of informed patient decisions — decisions employers have the power to influence.

To read the full story, login below.

Not a subscriber?

Start your subscription today!